Amarin News

Company Name Stock Ticker Symbol Market Type
Amarin Corp PLC AMRN NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.05 3.11% 1.66 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.60 1.5885 1.69 1.65 1.61
more quote information »

Recent News

Date Time Source Heading
8/12/20228:00IHNWFeaturedInnerScope Hearing Technologies (OTC: INND) Reports Record Revenues for a Profitable Q2 2022
8/05/202217:17EDGARSecurities Registration: Employee Benefit Plan (s-8)
8/05/202206:37TRMNH.C. Wainwright Remains a Hold on Amarin (AMRN)
8/04/202223:22TRMNAmarin (AMRN) Gets a Hold Rating from SVB Securities
8/03/202207:13EDGARQuarterly Report (10-q)
8/03/202207:09EDGARCurrent Report Filing (8-k)
8/03/202207:00GLOBEAmarin Reports Second Quarter 2022 Financial Results and..
7/22/202205:50TRMNJefferies Sticks to Its Hold Rating for Amarin (AMRN)
7/20/202208:00GLOBEAmarin to Report Second Quarter 2022 Financial Results and..
7/13/202208:00GLOBENICE Issues Final Guidance for Reimbursement Making VAZKEPA®..
6/30/202217:21EDGARCurrent Report Filing (8-k)
6/30/202216:05GLOBEREDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows..
6/16/202206:05EDGARAmended Statement of Beneficial Ownership (sc 13d/a)
6/15/202216:50BWSarissa Capital Intends to Vote “Abstain” at the Amarin..
6/10/202206:00GLOBEAmarin Receives Positive Recommendation from United..
6/06/202216:36EDGARCurrent Report Filing (8-k)
6/06/202208:30GLOBEAmarin Announces Comprehensive Cost Reduction Plan to..
6/06/202208:15GLOBEAmarin Appoints Tom Reilly as New Chief Financial Officer
6/03/202209:18EDGARAmended Statement of Beneficial Ownership (sc 13d/a)
5/24/202217:17EDGARProxy Statement (definitive) (def 14a)
5/24/202207:28PRNCAHLS Therapeutics Obtains Public Reimbursement for Vascepa®..
5/20/202207:48EDGARCurrent Report Filing (8-k)
5/19/202208:23GLOBEAmarin Announces Appointment of New Directors and Board..
5/16/202208:00GLOBEResearch Presented at the American Heart Association’s..
5/12/202208:00GLOBEAmarin to Present at Two Upcoming Investor Conferences
5/05/202207:25TRMNAmarin Nosedives on Disappointing Quarterly Results
5/04/202207:10EDGARCurrent Report Filing (8-k)
5/04/202207:07EDGARQuarterly Report (10-q)
5/04/202207:00GLOBEAmarin Reports First Quarter 2022 Financial Results and..
5/03/202208:00GLOBENew Analysis Reveals Icosapent Ethyl Significantly Reduces..
5/02/202216:03EDGARAmended Annual Report (10-k/a)
4/26/202208:49GLOBEAmarin Partner HLS Therapeutics Completes Reimbursement..
4/19/202207:30GLOBEAmarin to Report First Quarter 2022 Financial Results and..
4/17/202208:36TRMNAnalysts’ Top Healthcare Picks: Align Tech (ALGN), Amarin..
4/01/202207:00GLOBEEicosapentaenoic Acid (EPA) Combined with Widely Used..
3/31/202218:13SEEKAOUT, IMRX and AMRN among after hour movers
3/28/202208:45SEEKAmarin wins national reimbursement for Vazkepa in Sweden
3/28/202207:00GLOBEAmarin Receives Reimbursement for VAZKEPA® in Sweden
3/21/202208:30GLOBELatest Research Evaluating VASCEPA® (Icosapent Ethyl) to be..
3/15/202215:23SEEKAmarin recovers amid positive views from Piper Sandler on..
3/10/202209:23SEEKAmarin analysis shows Vascepa reduces risk of fatal..
3/10/202208:47GLOBELatest analysis shows VASCEPA® (icosapent ethyl)..
3/01/202207:42SEEKAmarin stock rises after Q4 earnings beat amid Vascepa..
3/01/202206:02SEEKAmarin Non-GAAP EPS of $0.06 beats by $0.09, revenue of..
3/01/202206:00GLOBEAmarin Reports Fourth Quarter and Full Year 2021 Financial..
2/28/202214:15SEEKAmarin Q4 2021 Earnings Preview
2/25/202208:00GLOBEAmarin to Participate in Cowen 42nd Annual Health Care..
2/24/202207:30GLOBEJAMA Publication Highlights VASCEPA® (Icosapent Ethyl)..
2/16/202208:00IHNWBiopharma Companies Setting up for a Rebound in the Near..
2/15/202208:00GLOBEAmarin to Report Fourth Quarter and Full Year 2021 Financial..
2/14/202216:22EDGARAmended Statement of Ownership (sc 13g/a)

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now